이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Leap Therapeutics 관리

관리 기준 확인 3/4

Leap Therapeutics' CEO는 Doug Onsi, Jan2011 에 임명되었습니다 의 임기는 13.42 년입니다. 총 연간 보상은 $ 1.53M, 43.6% 로 구성됩니다. 43.6% 급여 및 56.4% 보너스(회사 주식 및 옵션 포함). 는 $ 142.88K 가치에 해당하는 회사 주식의 0.19% 직접 소유합니다. 142.88K. 경영진과 이사회의 평균 재임 기간은 각각 4.2 년과 7.4 년입니다.

주요 정보

Doug Onsi

최고 경영자

US$1.5m

총 보상

CEO 급여 비율	43.6%
CEO 임기	13.4yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	4.2yrs
이사회 평균 재임 기간	7.4yrs

최근 관리 업데이트

Recent updates

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

Mar 13

Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth

Mar 03

Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?

Jan 27

Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year

Dec 23

Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)

Nov 18

CEO 보상 분석

Doug Onsi 의 보수는 Leap Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$53m
Dec 31 2023	US$2m	US$669k	-US$81m
Sep 30 2023	n/a	n/a	-US$81m
Jun 30 2023	n/a	n/a	-US$82m
Mar 31 2023	n/a	n/a	-US$86m
Dec 31 2022	US$2m	US$637k	-US$55m
Sep 30 2022	n/a	n/a	-US$53m
Jun 30 2022	n/a	n/a	-US$49m
Mar 31 2022	n/a	n/a	-US$42m
Dec 31 2021	US$2m	US$596k	-US$41m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$32m
Mar 31 2021	n/a	n/a	-US$29m
Dec 31 2020	US$2m	US$513k	-US$38m
Sep 30 2020	n/a	n/a	-US$39m
Jun 30 2020	n/a	n/a	-US$40m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	US$817k	US$400k	-US$33m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$22m
Mar 31 2019	n/a	n/a	-US$21m
Dec 31 2018	US$682k	US$400k	-US$23m
Sep 30 2018	n/a	n/a	-US$31m
Jun 30 2018	n/a	n/a	-US$31m
Mar 31 2018	n/a	n/a	-US$31m
Dec 31 2017	US$3m	US$397k	-US$30m

보상 대 시장: Doug 의 총 보상 ($USD 1.53M )은 US 시장( $USD 683.56K ).

보상과 수익: Doug 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Doug Onsi (55 yo)

13.4yrs

테뉴어

US$1,534,507

보상

Mr. Douglas E. Onsi, also known as Doug, J.D., serves as Director at Leap Therapeutics, Inc. since March 18, 2020. He serves as Managing Director of HCV Management VIII, LLC (formerly known as HealthCare V...

리더십 팀

이름	위치	테뉴어	보상	소유권
Douglas Onsi	CFO, General Counsel	13.4yrs	US$1.53m	0.19% $ 144.3k
Augustine Lawlor	Chief Operating Officer	8.4yrs	US$1.00m	0.013% $ 10.0k
Cynthia Sirard	Chief Medical Officer	4.2yrs	US$999.40k	0.013% $ 9.8k
Jason Baum	Chief Scientific Officer	1.2yrs	데이터 없음	데이터 없음
Mark O'Mahony	Chief Manufacturing Officer	4.2yrs	데이터 없음	0.013% $ 9.8k
Christine Granfield	VP and Head of Regulatory Affairs & Quality	3.8yrs	데이터 없음	데이터 없음

4.2yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: LPTX 의 관리팀은 경험 ( 4.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Douglas Onsi	CFO, General Counsel	4.3yrs	US$1.53m	0.19% $ 144.3k
Christopher Mirabelli	Chairman	13.4yrs	US$744.18k	0.013% $ 10.0k
James Cavanaugh	Independent Director	8.4yrs	US$126.62k	0% $ 0
Thomas Dietz	Lead Independent Director	8.4yrs	US$188.86k	0% $ 0
Nissim Mashiach	Independent Director	7.4yrs	US$118.24k	0% $ 0
Joseph Loscalzo	Independent Director	8.4yrs	US$112.12k	0% $ 0
William Li	Independent Director	7.4yrs	US$121.62k	0% $ 0
Carl Nathan	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Richard Schilsky	Independent Director	1.8yrs	US$112.12k	0% $ 0
Richard Brian Gaynor	Member of Scientific Advisory Board	3.4yrs	데이터 없음	데이터 없음
David Tuveson	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Andrew Nixon	Member of Scientific Advisory Board	3.4yrs	데이터 없음	데이터 없음

7.4yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: LPTX 의 이사회는 경험(평균 재직 기간 7.4 년)으로 간주됩니다.

Leap Therapeutics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024

Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of Directors

Leap Therapeutics, Inc. Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Leap Therapeutics, Inc. Resigns Dr. Monica Bertagnolli, as Director

Insufficient new directors

Insufficient new directors

Recent updates

Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024

Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP

Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium

Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics Announces Reverse Stock Split to Meet the Minimum Nasdaq Listing Price Per Share Requirements

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

Price target decreased by 10.0% to US$2.70

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

Leap Therapeutics, Inc. (NasdaqGM:LPTX) acquired Flame Biosciences, Inc from Acuta Capital Partners LLC, Adage Capital Management, L.P., Cormorant Asset Management, LP, Cormorant Asset Management, LP, Terra Magnum Capital Partners and others.

Price target decreased to US$3.60

Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of Directors

Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021)

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces First Patient Enrolled in Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 Distinguish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq at the ESMO Congress

Leap Therapeutics, Inc. Resigns Dr. Monica Bertagnolli, as Director

First half 2022 earnings released

Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05

Price target decreased to US$4.40

Leap Therapeutics and BeiGene, Ltd. Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer

Leap Therapeutics begins trials of DKN-01 in gastric/colorectal cancers

Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022

Consensus forecasts updated

Leap Therapeutics, Inc. to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting

Consensus revenue estimates increase by 99%

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Situation

Insufficient new directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Leap Therapeutics: Waiting For One More Leap

Leap Therapeutics to Present Positive New Data from the Distinguish Study of DKN-01 Plus Tislelizumab at the Asco GI Cancers Symposium

We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash Wisely

Insufficient new directors

Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.092 loss in 3Q 2020)

Leap Therapeutics: All On The Line

Price target increased to US$4.50

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Leap Therapeutics to Present New Data from the Distinguish Study of Dkn-01 Plus Tislelizumab At the Esmo 2021 Congress

Price target decreased to US$4.00

First half 2021 earnings released: US$0.24 loss per share (vs US$0.57 loss in 1H 2020)

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Consensus forecasts updated

Consensus forecasts updated

Leap Therapeutics, Inc. Provides DKN-01 Development Update

Revenue and earnings miss expectations

Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth

New 90-day high: US$2.63

Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?

New 90-day high: US$2.42

Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year

New 90-day high: US$2.37

Analysts update estimates

Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)

Revenue beats expectations, earnings disappoint

Leap Therapeutics, Inc. Announces the Presentation of Clinical Data from Its Phase 1b/2a Clinical Trial of DKN-01 in Patients with Advanced Esophagogastric Cancer

New 90-day low: US$1.53

New 90-day high: US$2.19

Leap Therapeutics, Inc. announced that it has received $26.985796 million in funding from Perceptive Advisors LLC, BeiGene, Ltd., Baker Bros. Advisors LP

Leap Therapeutics, Inc. Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer

Leap Therapeutics and Beigene Announces First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer

New 90-day low - US$1.76

Analysts update estimates

New 90-day low - US$1.77